Servicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Clin Transl Oncol. 2012 Jul;14(7):528-35. doi: 10.1007/s12094-012-0836-9.
Gastric adenocarcinomas are tumours of decreasing incidence in the Western world, although they are still the fourth leading cause of cancer mortality. The purpose of these clinical guidelines is to provide recommendations for the diagnosis and treatment of this disease based on the best available evidence. Regarding resectable gastric cancer, the various potential therapeutic options are discussed (adjuvant or perioperative chemotherapy, and adjuvant or neoadjuvant chemoradiotherapy). With regard to advanced or metastatic disease, different alternative combinations of conventional cytotoxic agents including a platinum agent (cisplatin or oxaliplatin) and a fluoropyrimidine (5-FU, capecitabine or S1), with or without a third drug (epirubicin or docetaxel), as well as their integration with new biological agents (trastuzumab in HER2+ tumours), are discussed. Finally, an outline is provided of the main lines of research and development of therapies for this disease.
胃腺癌在西方国家的发病率呈下降趋势，但仍是癌症死亡的第四大主要原因。本临床指南旨在根据现有最佳证据，为该疾病的诊断和治疗提供建议。对于可切除的胃癌，讨论了各种潜在的治疗选择（辅助或围手术期化疗，以及辅助或新辅助放化疗）。对于晚期或转移性疾病，讨论了不同的常规细胞毒药物联合方案，包括铂类药物（顺铂或奥沙利铂）和氟嘧啶类药物（5-FU、卡培他滨或 S1），以及联合或不联合第三种药物（表柔比星或多西他赛），并探讨了将其与新型生物制剂（曲妥珠单抗用于 HER2+肿瘤）联合应用的情况。最后，概述了该疾病治疗方法的主要研究和开发方向。
